Virtual Conference
Neuroscience conference 2022

Evgenia I Voronova

Sechenov First Moscow State Medical University, Russian Federation

Title: Cariprazine in schizophrenia with predominantly negative symptoms: Early effects at the first stage of therapy (observational study)


Background: Limited efficacy of antipsychotics against negative symptoms in schizophrenia and new drugs with wider spectrums of clinical efficacy are very desirable. The newer 3rd generation antipsychotic Cariprazine with unique mode of action – partial agonist predominantly for dopamine D3- and in lesser extent D2-receptors found to be effective in the treatment of negative symptoms in schizophrenia comparing to second generation antipsychotic risperidone.

Objectives: To evaluate initial effects of Cariprazine in schizophrenia patients with predominantly negative symptoms.

Design and patients: Open-lable observational study included 60 adult schizophrenia patients (F20 on ICD-10, 49% males) with predominantly negative symptoms (PANSS-FSNS ? 15, PANSS-FSPS < 19) treated with Cariprazine (starting daily dose 1,5 mg followed by upward titration by 1,5 mg weekly up to 6 mg if needed) were assessed with PANSS, CAINS, CDSS and SAS scales at baseline and on week 1, 2, and 4. 

Results: Most patients (75%) improved during 28 days of cariprazine treatment. At the end of assessment (day 28) mean starting total scores for negative symptoms on PANSS-NS and CAINS scales significantly (p<0.05) reduced by 4,3 and 4,9 respectively with no significant changes in depression symptoms (CDSS). Cariprazine tolerability was very good, only 4 patients discontinued because of TEAEs (akathisia, insomnia).

Conclusions: The results of this observational study suggest early effect of Cariprazine on negative symptoms at least in some schizophrenia patients with predominantly negative symptoms starting from 1-2 weeks of treatment and could be useful for determination of early clinical predictors for efficacy. Considering limitations of observational open-lable design with no control groups these data need to be confirmed.


Evgenia I. Voronova after graduating in 1994 from the Moscow Medical Stomatological Institute. N.A. Semashko (medical business) studied in an internship in the specialty "Therapy"; in 2003 she completed her specialization in Psychiatry. Since 1999 he has been working at the First Moscow State Medical University. THEM. Sechenov at the Department of Psychiatry and Psychosomatics. Currently, E. Voronova is an associate professor at the Sechenov University and part-time - a leading researcher at the Federal State Budgetary Scientific Institution "Scientific Center for Mental Health". Research interests - affective disorders, schizophrenia and schizophrenia spectrum disorders, therapy of mental disorders. Author of 40 scientific publications (including chapters in monographs). Executive secretary of the editorial board of the journal "Mental disorders in general medicine", member of the Russian Society of Psychiatrists.